ALAbhishek Lenka

Abhishek Lenka

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Abhishek Lenka has a total of 60 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Revisiting Parakinesia Brachialis Oscitans: You Yawn, I Move! A Scoping Review

    by Rani Priyanka Vasireddy, Ricardo A. Vivanco, Aishwarya Koppanatham, Abhishek Lenka

    Background: Parakinesia brachialis oscitans (PBO) is a rarely reported phenomenon in which a paretic limb moves involuntarily during yawning. The literature consists predominantly of case reports and small series, with limited comparative evidence. Methods: We conducted a PRISMA-ScR-guided scoping review of PubMed, Embase, and Web of Science from inception to 28 August 2026, with backward citation searching. Eligible reports described one or more patients with an involuntary, stereotyped, yawn-locked movement of a paretic limb after a focal central nervous system lesion, with the lesion site reported on neuroimaging. Data included demographics, movement description, latency, lesion site, etiology, and outcome. Results: Twenty-two reports describing 31 patients met the inclusion criteria. Most patients were men (67.7%), with a mean age of 56.1 years. PBO involved the upper limb alone in 29 patients (93.5%). Acute ischemic stroke was the most common etiology (83.9%). Lesions were often seen in the internal capsule (44.4%) and the corona radiata or subcortical white matter (40.7%). Onset ranged from immediate to four months after the lesion. Complete resolution was documented in 10 patients (32.3%), PBO persisted for up to three years in five, and outcome was not reported in 15 (48.4%). Discussion: PBO is associated with focal lesions affecting distributed voluntary motor-control networks, frequently involving subcortical motor pathways. Although no mechanism has been established, the observations suggest a release of preserved brainstem and extrapyramidal circuits. Outcome was unreported in almost half the cases; prospective, standardized reporting is needed to clarify its course and prognostic significance. Highlights This scoping review gathered 22 reports describing 31 patients with PBO after a focal brain injury. PBO involved the upper limb alone in 29 patients and lesions were most commonly subcortical, involving the internal capsule. Onset ranged from presentation to four months and PBO persisted for up to three years. However, the outcome was not reported in half of the included cases.

  • A framework for multidisciplinary management of autonomic dysfunction in Parkinson disease

    by Cameron Miller-Patterson, Delaram Safarpour, Katherine Longardner, Guillaume Lamotte, Abhishek Lenka, Abhimanyu Mahajan, Sarah Diamond, Ankita Gupta, Julie Hershberg, Sahib Khalsa, et al.


  • Clinical Reasoning: A 66-Year-Old Man With Chronic Orthostatic Hypotension

    by Abhishek Lenka, Steven Vernino

    A 66-year-old man presented with a 9-year history of chronic orthostatic intolerance and recurrent syncope. A review of systems also revealed several other symptoms including dry eyes and mouth, chronic nausea and bloating, constipation, urinary urgency and urge incontinence, and erectile dysfunction. He had no motor, sensory, or cognitive concerns. He took no medications that could cause autonomic dysfunction. His neurologic examination was unremarkable. The tilt table test revealed neurogenic orthostatic hypotension. His plasma norepinephrine level was low. Eventually, a treatable etiology of autonomic failure was identified, and the patient had excellent response to treatment.

  • Approach to Cardiovascular Autonomic Dysfunction in Patients with Synucleinopathies

    by Abhishek Lenka, Paul Beach

    Background: Autonomic dysfunction is a common feature of synucleinopathies such as Parkinson's disease (PD), dementia with Lewy bodies (DLB), multiple system atrophy (MSA), and pure autonomic failure (PAF). Orthostatic hypotension (OH) and supine hypertension (SH) are hallmark manifestations of cardiovascular autonomic dysfunction that are increasingly recognized as contributors to long‐term adverse clinical outcomes such as accelerated cognitive decline, motor symptom exacerbation, and end‐organ damage. Several atypical presentations of OH, including coat‐hanger pain, cognitive fluctuation, postural instability, fatigue, exertional dyspnea, and falls, commonly overlap with motor and non‐motor features of synucleinopathies. This clinical overlap highlights the need for heightened awareness of the diverse and often subtle manifestations of OH in affected individuals. Although the general management of OH has been addressed in prior literature, a dedicated framework tailored to the pathophysiological and clinical nuances specific to synucleinopathies remains lacking. SH, despite its high prevalence and significant prognostic implications, has received minimal attention in existing reviews and is often overlooked in clinical practice. Objective: Given the growing recognition of cardiovascular autonomic dysfunction as a potentially modifiable contributor to disease progression and patient quality of life, a focused updated review is warranted to inform clinical decision‐making and guide future research in this evolving area. Results: This narrative review comprehensively discusses the approach to OH and SH in the context of synucleinopathies. Conclusions: The key topics addressed are the pathophysiology of OH and SH in synucleinopathies, diagnostic criteria and types of OH, diagnostic criteria of SH, and management strategies (non‐pharmacological, pharmacological, and novel/experimental).


  • Open Access

    Neurology Residency Training in 2022

    by Brian E. Emmert, Abhishek Lenka, Jessica Frey, Laura A. Gilbert, Tasha Ostendorf, Carol E. Rheaume, Gauri V. Pawar


  • Carbidopa: beyond Parkinson’s disease

    by Abhishek Lenka, Steven Vernino

    Purpose To revisit the pharmacology and real-world use of carbidopa in the management of autonomic disorders. Methods To identify articles suitable for this review, a search of the PubMed database was conducted in January 2025 using the keywords “Carbidopa,” “MK-486,” and “L-alpha-methyldopa hydrazine.” Results The pharmacotherapeutic role of carbidopa extends beyond the management of Parkinson’s disease. Our literature search revealed the use of carbidopa in three primary autonomic diseases to treat either nausea or symptoms of sympathetic hyperactivity: (1) familial dysautonomia, (2) hyperadrenergic postural orthostatic tachycardia syndrome (POTS), and (3) afferent baroreflex failure (familial or acquired). Even at a dose as high as 600 mg/day, carbidopa was not associated with bothersome side effects in some of the clinical trials on familial dysautonomia. Pre-clinical evidence also suggests in vitro and in vivo inhibition of T-cell activation by carbidopa and a potential therapeutic use in cytokine release syndrome. Conclusion Current evidence, although limited, suggests that carbidopa has a favorable safety profile. While large, well-designed studies are warranted, observations from case series and small studies suggest that carbidopa could have utility in treating nausea in familial dysautonomia and symptoms of sympathetic hyperactivity in hyperadrenergic postural orthostatic tachycardia syndrome (POTS) and afferent baroreflex failure.


  • Corticobasal Syndrome

    by Abhishek Lenka, Joseph Jankovic

    Corticobasal syndrome (CBS) is a complex of symptoms and signs comprising limb rigidity, bradykinesia, dystonia, myoclonus, apraxia, cortical sensory loss, and a variety of cognitive and language impairments. CBS is commonly seen in tauopathies. Striking asymmetry in clinical and imaging findings in CBS raises questions about potential triggers initiating neurodegeneration. The objective of this study was to investigate potential central or peripheral triggers preceding CBS symptoms. In this retrospective observational study, we reviewed medical records of patients with CBS at our Parkinson's Disease Center and Movement Disorders Clinic, focusing on evidence of possible central or peripheral "trigger" occurring within a year before the onset of CBS. We also reviewed records of patients with Parkinson disease (PD) for comparison. Of the 72 patients with CBS, 15 (20.8%) reported potential focal triggers before the onset of CBS-related neurologic symptoms. By contrast, only 1 of 72 patients with PD (1.4%) had a documented trigger before the onset of PD-related symptoms (p < 0.001). Of potential triggers, 13 were peripheral (related to hand or shoulder surgeries or trauma) and 2 were central (stroke and head trauma). Patients with CBS with triggers were younger, had earlier symptom onset, comprised a higher proportion of men, and had a higher likelihood of limb onset of symptoms than those without. Our finding of relatively high frequency of focal triggers in CBS compared with PD suggests potential central or peripheral triggers initiating neurodegeneration, possibly explaining asymmetric clinical and imaging features in CBS. Further research is necessary to validate and explore this observation's implications for CBS pathogenesis.


  • Catatonia Classification and Deep Phenotyping: The Effect of Affect Must Not Be Overlooked

    by Abhishek Lenka, Vishal M. Perera, Alberto J. Espay, Gregory M. Pontone, Michael S. Okun

  • Open Access

    Movement Disorders in Brain Sagging Syndrome Due To Spontaneous Intracranial Hypotension: A Review

    by Abhigyan Datta, Alfonso Fasano, Abhishek Lenka

    Tremor and Other Hyperkinetic Movements (TOHM) [ISSN: 2160-8288], a fully open access peer-reviewed journal, publishes clinical and scientific papers on tremor and hyperkinetic movements. TOHM is indexed in PubMed and PubMed Central. In contrast to other publications focusing on disorders of hypokinesia (i.e., mainly Parkinson’s disease), TOHM emphasizes the hyperkinetic movements, giving center stage to clinical observations and research in this area. Papers on Parkinson’s disease and related disorders will be considered if they relate to the hyperkinetic features of these diseases (e.g., tremor, dystonia, dyskinesias). The average turnaround time from submission to first decision is roughly 24 days (~3.5 weeks). The average turnaround time from acceptance to publication is 18 days (~2.5 weeks) with a median of 14 days (2 weeks). Tremor and Other Hyperkinetic Movements is indexed with the Web of Science Emerging Sources Citation Index. As of 2024, Tremor has a Journal Impact Factor of 2.5.